Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: antibodies + antibody + control  Related to the article below (Last Update: 8/5/2008)

YM BIOSCIENCES REPORTS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC ...
FOXBusiness - 34 minutes ago
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor. In clinical trials and commercial sales of nimotuzumab ...YMI

Canada.com
US HIV incidence 40% higher than previous estimates, new test shows
Aidsmap, UK - Aug 3, 2008
Standard HIV antibody tests show whether a person has the virus, but cannot determine how recently infection occurred. Furthermore, due to confidentiality ...
US government wrong on HIV rates Real News Network
The Past, Present, and Future of AIDS Journal of American Medical Association (subscription)
all 1,265 news articles »
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a ...
華富財經, Hong Kong - Jul 30, 2008
They assessed the effects of the antibody on levels of amyloid beta in the blood and cerebrospinal fluid, as an indirect measure of the effect of the ...LLY
Chembio Reports Record Total Revenues in Second Quarter
MarketWatch -
... the three DPP(R) products in connection with our contract with the Brazilian Ministry of Health; tests for antibody detection of canine Leishmaniasis, ...
ImClone Systems Issues Statement
FOXBusiness -
Additionally, Mr. Icahn pointed out that ImClone has a pipeline antibody, IMC-11F8, under development which, if ultimately approved for sale, ...IMCL - BMY
XOMA Begins Phase 2a Clinical Trial to Evaluate XOMA 629 Topical ...
MarketWatch - Jul 24, 2008
The Company's expanding pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 629, a synthetic antimicrobial peptide compound derived from ...XOMA
Vical Reports Second Quarter and First Six Months 2008 Financial ...
PR Newswire (press release), NY -
... for the first time that DNA vaccines have achieved potentially protective levels of antibody responses in humans with no significant safety issues. ...VICL - TYO3:4563
MorphoSys AG: First AbD Serotec Generated HuCAL Antibodies ...
MarketWatch - Jul 16, 2008
"Today's news marks the first market entry of a clinical diagnostic kit comprising a HuCAL antibody," commented Dr. Simon Moroney, Chief Executive Officer ...FRA:MOR - OTC:CMTX
Roche Agrees to Buy ARIUS Research for C$191 Million (Update1)
Bloomberg - Jul 23, 2008
Switzerland's biggest drugmaker also said July 21 it wants to gain total control of US unit Genentech Inc., in which it already holds a majority stake. ...
Roche to acquire antibody expert Arius in C$191 million deal Pharma Times (subscription)
all 72 news articles »  TSE:ARI - OTC:RHHBY - SWF:RO
Regeneron Reports Second Quarter 2008 Financial and Operating Results
MarketWatch - Jul 31, 2008
The first therapeutic antibody to enter clinical development under the collaboration is REGN88, an antibody to the interleukin-6 receptor (IL-6R) that is ...REGN
Source: Google News

Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. -
M Shah, DM Foreman, MW Ferguson - Lancet, 1992 - ncbi.nlm.nih.gov
... All control wounds (irrelevant antibody, or TGF-beta, or no injection) healed with
scarring, whereas the NA-treated wounds healed without scar-tissue formation ...

… human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with … -
F Ofei, S Hurel, J Newkirk, M Sopwith, R Taylor - Diabetes, 1996 - ncbi.nlm.nih.gov
1996 Jul;45(7):881-5. Effects of an engineered human anti-TNF-alpha antibody (CDP571)
on insulin sensitivity and glycemic control in patients with NIDDM. ...

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity -
K Ichikawa, W Liu, L Zhao, Z Wang, D Liu, T … - Nature Medicine, 2001 - nature.com
... antibody against mouse IgG1. The open histograms represent the isotype antibody
control and solid histograms represent TRA-8 staining. ...

Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to … -
R Hussain - The Journal of Immunology, 1992 - Am Assoc Immnol
... This control of clinical allergic reactivity likely results from Ag-specific IgG
"blocking antibodies" shown previously to be abundant in the sera of such ...

… Factor Receptor-2-blocking Antibody Potentiates Radiation-induced Long-Term Control of Human Tumor … -
SV Kozin, Y Boucher, DJ Hicklin, P Bohlen, RK Jain … - Cancer Research, 2001 - AACR
... Advances in Brief. Vascular Endothelial Growth Factor Receptor-2-blocking Antibody
Potentiates Radiation-induced Long-Term Control of Human Tumor Xenografts 1. ...

T cell control of antibody production.
RK Gershon - Contemp Top Immunobiol, 1974 - ncbi.nlm.nih.gov
Contemp Top Immunobiol. 1974;3:1-40. T cell control of antibody production.
Gershon RK. Publication Types: Review. MeSH Terms: Animals; ...

CONTROL OF ANTIDONOR ANTIBODY PRODUCTION WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL IN RENAL … -
TP Theruvath, SL Saidman, S Mauiyyedi, FL … - Transplantation, 2001 - transplantjournal.com
... CONTROL OF ANTIDONOR ANTIBODY PRODUCTION WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL
IN RENAL ALLOGRAFT RECIPIENTS WITH CHRONIC REJECTION 1. ...

… Suppression of Tumor Vascular Permeability After Administration of Antibody to Vascular Endothelial … -
CD Pham, TPL Roberts, N Van Bruggen, O Melnyk, J … - Cancer Investigation, 1998 - informaworld.com
... Representative axial magnetic resonance images of tumor-bearing animals given either
anti-gpl20 antibody (control) or anti-VEGF antibody before contrast ...

Temporal association of cellular immune responses with the initial control of viremia in primary … -
RA Koup, JT Safrit, Y Cao, CA Andrews, G McLeod, W … - J Virol, 1994 - pubmedcentral.nih.gov
... CTL: virus control cells first and cytolytic cells second? ... Development of HIV-1
group-specific neutralizing antibodies after seroconversion. AIDS. ...

GENETIC CONTROL OF THE ANTIBODY RESPONSE I. DEMONSTRATION OF DETERMINANT-SPECIFIC DIFFERENCES IN … -
HO McDevitt, M Sela - Journal of Experimental Medicine, 1965 - Rockefeller Univ Press
... pre- sented detailed evidence using inbred guinea pigs that antibodies to different
antigenic determinants on the insulln molecule are under genetic control. ...

Source: Google Scholar

Personalised Medicine: Therapy Control Of Humanised Antibodies

CENiMED GmbH, BioTeZ Berlin-Buch GmbH and Invitek Gesellschaft für Biotechnik & Biodesign mbH (company for biotechnology and bio-design) announce their cooperation in the development, production and marketing of Recovery-ELISAs for therapy control of a new group of therapeutics, the so called humanised antibodies.

Humanised antibodies offer unforeseen potentialities in cancer therapy, e. g. for the treatment of mamma carcinoma. Previous therapy control methods, however, could not avoid overdoses which had caused adverse reactions with the patients. Recovery-ELISA (R-ELISA) is an innovative, patented ELISA technique for the determination of the exact efficacy concentration of the therapeutic antibodies and the therapy control.
The automation of this technique will be established by a renowned platform manufacturer and then will be made available for the patients and the pharmaceutical industry.

"For the first time possibilities for a patient-specific therapy with humanised antibodies will be available" expresses Dr. Bendzko, CEO of Invtek Gesellschaft für Biotechnik & Biodesign mbH.

Dr. Pavel Strohner, CEO of BioTeZ Berlin-Buch GmbH and developer of this novel R-ELISA test, is a leading expert in the field of ELISA technology. The Berlin location is proud of this epochal development. This is yet another demonstration of the potentials and successes of a cooperation of several innovative biotechnological companies.

"This is yet another important milestone for the implementation of personalised medicine with the patients" complements Dr. Volker Muschalek, CEO of CENiMED GmbH.

About CENiMED GmbH

CENiMED GmbH - Centre for Individualised Medicine - was established in 2003 as a spin-off of the Charité Universitätsmedizin Berlin, Germany, with the intention to commercialise the results of medical fundamental research in the field of pharmacogenomics. It is a leading bio-medical company in the area of pharmacogenomic services. The company focuses on the development and marketing of services and products for the pharmaceutical industry. Herewith, CENiMED supports their clients from the early phases of drug development to post marketing studies. CENiMED is located in the Biotech Park, Berlin-Buch, Germany and possesses state-of-the-art genotyping and gene expression laboratories. Its mission is the development of early diagnostic and prognostic products on the basis of patent specific biomarkers.

About BioTeZ GmbH

Biotez Berlin-Buch GmbH, is a biotechnologically oriented company, was established 10 years ago and is situated on the Biotech campus Berlin-Buch since 1992

BioTeZ focuses on the following areas: Bio-diagnostics and food analytics, scientific services for genetic research and biotechnology and Custom oligonucleotide synthesis.

Additionally, the companies' experts have special experience and know-how in the conjugation and labelling of bio molecules (with HRP, FITC a. o.), development of monoclonal and polyclonal antibodies, ELISA development, Streptavidin coating (high biotin binding capacity, high chemo- and thermo stability) and immuno-affinity columns and chromatography.

About Invitek Gesellschaft für Biotechnik & Biodesign mbH

Invitek GmbH is a world-wide operating company that offers innovative products and technical support for the Life Science and diagnostics industries.

Founded in 1992, the company is known internationally for its outstanding and powerful technology platforms and also offers a wide range of innovative products for the nucleic acid purification, molecular diagnostics, the pharmaceutical industry and bio medical research. Within the modular product concept "I-tek solution", Invitek combines its technological developments in complete solutions for molecular diagnostics. An example is the successful introduction of an early warning system for colon carcinoma.

The company is certified according to DIN EN ISO 9001:2000 and EN ISO 13485:2003 and manufactures according to EC Directive 98/79/EEC (IVD-MD).

http://www.invitek.de
http://www.biotez.de
http://www.cenimed.com
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.